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Transforming Growth Factor β1 (TGFβ1) is a crucial cytokine triggering myofibroblastic (MF) differentiation, a process involved in tissue
healing as well as in pathologic conditions such as fibrosis and cancer. Together with cell shape modifications, TGFβ1-mediated differentiation of
fibroblasts into myofibroblasts is characteristically associated with the neo-expression of smooth muscleα-actin (α-SMA), a cytoskeletal protein that
enhances their contractile activity. Several cellular differentiation programs have been linked to epigenetic regulation of gene expression, including
gene methylation and histone acetylation. Herein, we sought to investigate the role of histone deacetylases (HDAC) in TGFβ1-induced MF
differentiation. We found that TSA, a global inhibitor of class I and class II HDACs, prevented α-SMA transcript and protein expression and
morphological changes mediated by TGFβ1 in cultured human skin fibroblasts. In order to identify the HDAC(s) participating in MF differentiation,
the impact of specific HDAC silencing (HDAC1 through HDAC8) using RNA interference was investigated in fibroblasts exposed to TGFβ1.
Among the eight HDACs tested, silencing of HDAC4, HDAC6, and HDAC8 expression impaired TGFβ1-induced α-SMA expression. HDAC4
silencing most efficiently abrogated α-SMA expression and also prevented TGFß1-mediated morphological changes. Forced down-regulation of
HDAC4 stimulated the expression of 5′-TG-3′-Interacting Factor (TGIF) and TGIF2 homeoproteins, two known endogenous repressors of the TGFβ
signaling pathway, but not of the inhibitory Smad7. Collectively, these data suggest that HDAC4 is an essential epigenetic regulator of MF
differentiation and unveil HDAC4 as a potential target for treating MF-related disorders.
© 2007 Published by Elsevier B.V.Keywords: Histone deacetylase; TGFβ1; TSA; Myofibroblast; α-SMA; TGIF; Smad71. Introduction
Transforming growth factor β1 (TGFβ1) is the prototype of a
large family of growth factors that regulate a wide range of
biological processes, exerting their functions both during
embryogenesis, in terms of organogenesis and morphogenesis,
and in the adult organism, where they orchestrate complex
phenomena such as inflammation, tissue repair and neoplastic
transformation/progression [1]. TGFβ1 broad activities include,
among others, context-specific inhibition or stimulation of cell
proliferation, control of extracellular matrix (ECM) synthesis
and degradation, control of epithelial-to-mesenchymal transi-⁎ Corresponding author. Metastasis Research Laboratory, Pathology Building,
B23, level -1, University Hospital of Liège, B-4000 Liège, Belgium. Tel.: +32 4
366 4358; fax: +32 4 366 2975.
E-mail address: David.Waltregny@ulg.ac.be (D. Waltregny).
0167-4889/$ - see front matter © 2007 Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2007.05.016tion, mediation of cell and tissue responses to injury, control of
carcinogenesis, and modulation of immune functions. Remark-
ably, TGFβ1 is sufficient to induce the generation of granulation
tissue and angiogenesis in vivo and is the prominent growth
factor able to stimulate the differentiation of fibroblasts into
myofibroblasts, a process termed myofibroblastic (MF) differ-
entiation that contributes to the pathobiology of chronic fibrotic
disease [2–4].
The observation that mesenchymal cells are capable of trans-
forming into myofibroblasts during tissue repair and under
several pathologic conditions, including fibrocontractive dis-
eases (e.g. Dupuytren's disease or hypertrophic scars), fibrosis
(e.g. cirrhosis), and stromal reactions to tumor growth and
invasion, has been extensively documented [5,6]. One of the
main features of myofibroblasts is represented by an important
contractile apparatus [7], and in particular by the neo-expression
of the smooth muscle α-actin (α-SMA) isoform [8]. Myofibro-
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ate between fibroblasts and smooth muscle cells and are
recognized to play a central role in closing the wound tissue,
through their capacity to produce a strong contractile force
[6,9–11]. In fact, in addition to being a well-accepted marker of
myofibroblast differentiation, α-SMA has been shown to be
sufficient to enhance fibroblast contractile activity [12,13].
TGFβ1-mediated MF differentiation is accompanied by
changes in the expression of many genes, including cytoskeletal
proteins (e.g. α-SMA), ECM proteins (e.g. collagens type I and
III, fibronectin, and proteoglycans such as versican), and
proteins inhibiting ECM degradation (e.g. PAI-1, Timp-1)
[5,6]. TGFβ1 exerts its biological activities mainly through
transcriptional regulation of diverse genes. Upon binding of this
growth factor to its transmembrane serine/threonine kinase re-
ceptors, coregulatory proteins Sma- and Mad-related proteins
Smad2 and Smad3 are phosphorylated by the receptors, form
heterodimers with Smad4, and migrate into the nucleus to form
multisubunit transcriptional complexes regulating target gene
transcription [14–16]. TGFβ1 is able to mediate diverse
responses because of the interaction of Smad complexes in the
nucleus with different partner proteins that may be specific to a
particular cell type and for a given set of environmental con-
ditions [17]. Previously it has been suggested that the total
cellular levels of Smad transcriptional co-activators and co-re-
pressors factors play a critical role in controlling and fine-tuning
the biological responses to TGFβ [16]. These regulatory co-
factors may function by recruiting histone acetyltransferase
(HAT) and histone deacetylase (HDAC) activity to the target
promoter [17–19]. Thus, some of TGFβ-driven MF differentia-
tion-associated gene expression changes appear to be regulated
epigenetically, through modifications of DNA methylation and
histone acetylation levels. Recent data have also pointed at a role
of HATs and HDACs in modulating the acetylation levels – and
consequently the transcriptional activity– of Smad proteins [20].
In mammalian cells, HDACs constitute a family of 18 en-
zymes that regulate gene expression by modifying the acetyla-
tion level of nucleosomal histones and nonhistone proteins,
including several transcription factors and tumor suppressors.
These enzymes are usually separated into 3 classes on the basis
of their similarity to various yeast histone deacetylases: (i) class I
members (HDAC1, HDAC2, HDAC3, HDAC8, and HDAC11),
which are homologous to the yeast RPD3 protein (ii) class II
HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and
HDAC10), which have similarities to yeast HDA1 and, (iii)
sirtuin (SIRT) proteins, which are homologous to the yeast SIR2
protein and require nicotinamide adenine dinucleotide (NAD) as
a cofactor [21]. To date, 7 human SIRT homologues have been
uncovered. Accumulating evidence suggests that histone de-
acetylase family members are involved in numerous important
biological activities, ranging from hormone-induced gene
regulation to cell proliferation, differentiation, apoptosis and
senescence [21]. Previous reports have suggested that global
suppression of HDAC activities by inhibitors targeting both
class I and class II HDACs, inhibits both angiogenesis [22,23]
and TGFβ1-induced fibrogenesis[24–26], two important pro-
cesses occurring during wound healing.The present studywas aimed at (i) determining the influence of
global HDAC inhibition on TGFβ1-mediated MF differentiation
and (ii) identifying the HDAC(s) participating in this process.
TSA was found to prevent α-SMA transcript and protein
expression and morphological changes mediated by TGFβ1 in
primary human skin fibroblasts. Among the eight first HDAC
members tested, RNA interference-mediated silencing ofHDAC4
most efficiently abrogated TGFβ1-induced phenotypic trans-
formation. HDAC4 silencing was associated with an increased
expression of 5′-TG-3′-Interacting Factor (TGIF) and TGIF2, two
homeodomain proteins known to repress TGFβ activities.
Altogether, these data indicate that HDAC4 is a required
epigenetic mediator of MF differentiation driven by TGFβ1.
2. Materials and methods
2.1. Cell lines, reagents, and treatments
Primary human skin fibroblasts were established by outgrowth of normal
skin biopsies as previously described [27]. Different batches of these cells were
randomly selected for the experiments outlined below. Cells were maintained in
Dubelcco's modified Eagle's medium (DMEM) supplemented with 10%
decomplemented (heat-inactivated) fetal bovine serum (FBS; ICN Pharmaceu-
ticals, Costa Mesa, CA, USA), penicillin (100 units/mL), streptomycin (100 μg/
mL) and 2 mM L-glutamine at 37 °C in a humidified 95% air/5% CO2
atmosphere. Cells were sub-cultured by trypsinization (0.05% trypsin, 0.53 mM
EDTA) in phosphate-buffered saline (Dulbecco's PBS (DPBS) without calcium,
magnesium, and sodium bicarbonate). Cells were reseeded at a ratio of 1:3 and
used between passages 7 and 14. Absence ofmycoplasma infectionwas routinely
checked. All tissue culture reagents were obtained from Invitrogen (Merelbeke,
Belgium) unless otherwise specified.
Cells were treated with trichostatin A (TSA) (Sigma Chemical Company, St.
Louis, MO, USA) at a final concentration of 50, 200, or 500 nM in DMSO every
24 h and/or TGFβ1 (Roche Diagnostics, Indianapolis, IN, USA) at a final
concentration of 2.5 ng/mL in PBS every 24 h. Control conditions consisted of
cells incubated with vehicles alone. Twenty-four hours after initial plating, cells
were incubated with DMEM containing 1% FBS and the appropriate drug or
vehicle upon start of the experiment.
2.2. Small interfering RNA (siRNA) transfection
The siRNAs used in this study were synthesized by Eurogentec (Seraing,
Belgium) and Dharmacon (Lafayette, Colorado, USA) and were all made of 2
complementary nucleotide strands containing 21 bases. The sequences of the
oligonucleotides are provided in Table 1; most of them have been utilized in
previous studies [27–29]. Each pair of oligonucleotides was received annealed at
a concentration of 100 μM in 50 mMTris pH 7.5–8.0, 100 mMNaCl. Cells were
transfected at a starting confluence between 40% and 50%. Calcium phosphate-
mediated transfection was performed in 6-well plates with a final concentration
of 40 nM of each siRNA, unless otherwise specified.
After 16 h of transfection, cells were rinsed twice with PBS, incubated in 10%
FBSmediumwith or without TGFβ1 (2.5 ng/mL in PBS). Mediumwas changed
every 24 h and cells were collected following 48 h of treatment. Mock
transfections with transfection reagent alone served as negative control. Controls
also included three different RNA duplexes: a scrambled HDAC4 siRNA
(scHDAC4 siRNA) whose sequence corresponded to the reverse, and
subsequently modified (inversion of 4 bases), sequence of the HDAC4#2
siRNA, a siRNA directed against GL3 luciferase [30], and a negative control
siRNA designed by, and purchased from, Eurogentec (OR-0030-neg05).
2.3. Antibodies
Anti-HDAC4 antibody was raised against a synthetic peptide corresponding
to residues surrounding amino acid 10 of human HDAC4 (Cell Signaling
#2072). Anti-smooth muscle α-actin (α-SMA, clone 1A4) antibody was from
Table 1
siRNA oligonucleotidic sequences used
siRNA
designation
Target mRNA siRNA oligonucleotide sequence
HDAC1 HDAC1 5′-AAGCCGGUCAUGUCCAAAGUA-3′
5′-UACUUUGGACAUGACCGGCUU-3′
HDAC2 HDAC2 5′-GCCUCAUAGAAUCCGCAUGTT-3′
5′-CAUGCGGAUUCUAUGAGGCTT-3′
HDAC3 HDAC3 5′-AAUCAGAACUCACGCCAGUAU-3′
5′AUACUGGCGUGAGUUCUGAUU-3′
HDAC4#1 HDAC4 5′-GACGGGCCAGUGGUCACUGTT-3′
5′-CAGUGACCACUGGCCCGUCTT-3′
HDAC4#2 HDAC4 5′-CGACAGGCCUCGUGUAUGAUU -3′
5′-UCAUACACGAGGCCUGUCGUU -3′
HDAC4#3 HDAC4 5′-GAAUGUACGACGCCAAAGAUU-3′
5′-UCUUUGGCGUCGUACAUUCUU-3′
scHDAC4#2 None 5′-AGUCUGGUCCCGUGAAAGCUU-3′
5′-GCUUUCACGGGACCAGACUUU-3′
HDAC5 HDAC5 5′-AACAGCAUGACCACCUGACAA-3′
5′-UUGUCAGGUGGUCAUGCUGUU-3′
HDAC6 HDAC6 5′-CUGCAAGGGAUGGAUCUGATT -3′
5′-CUGCAAGGGAUGGAUCUGATT-3′
HDAC7 HDAC7 5′-GGACAAGAGCAAGCGAAGUTT-3′
5′-ACUUCGCUUGCUCUUGUCCTT-3′
HDAC8 HDAC8 5′-UGAGCCCCACCGAAUCCAATT-3′
5′-UUGGAUUCGGUGGGGCUCATT-3′
GL3 Luc GL3 Luciferase 5′-CUUACGCUGAGUACUUCGAUU-3′
5′-UCGAAGUACUCAGCGUAAGUU-3′
EGT None Eurogentec non disclosed sequence
(Cat N° OR-0030-Neg05)
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AC15) monoclonal antibodies were from Sigma-Aldrich (Bornem, Belgium).
Human osteosarcoma SaOS-2 cells transfected with a flag-tagged human
HDAC4 expression vector (kindly provided byDr. E. Verdin, Gladstone Institutes
of Virology and Immunology, UCSF, CA,USA) using FUGENE 6™ transfection
reagent were used as positive controls in the immunoblot experiments.
2.4. Western blot analysis
After rinses in PBS, in vitro grown subconfluent cells were scrapped in 1%
SDS containing phosphatase inhibitors (1mMNa3VO4) andComplete® protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Protein lysates
were cleared by centrifugation at 10,000×g for 1 min in 20 μm columns
(Machery-Nagel, Postfach, Düren, Germany). The shredded lysates were
retrieved and frozen at –80 °C until use in immunoblot assays. The protein
concentration was measured using a bicinchoninic acid determination kit (Pierce
Chemical Co., Rockford, IL, USA). Equal amounts of protein lysates were
resolved by size on 7.5%, 10% or 12% SDS-PAGE gels and transferred onto
nitrocellulose (Biorad, Hercules, CA, USA) or polyvinylidene difluoride (Roche
Diagnostics, Mannheim, Germany) membranes. Equal protein loading and
transferring was examined by Coomassie gel staining (data not shown) and β-
actin normalization. The membranes were blocked with 5% non-fat dry milk in
Tris-buffered saline (20 mM Tris base (pH 7.6), 150 mMNaCl) containing 0.1%
or 0.05% Tween-20 (TBS-T), and probed with the following primary antibodies:
anti-HDAC4, anti-α-SMA, anti-α-tubulin and anti-β-actin. After washing in
TBS-T, membranes were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (Bio-Rad Laboratories, Hercules, CA) and
developed using enhanced chemiluminescence detection system (ECL detection
kit; Amersham Corp., Arlington Heights, IL), according to the instructions of the
manufacturer. Membranes were exposed to Kodak X-Omat AR films.
2.5. Immunoperoxidase detection of smooth muscle α-actin (α-SMA)
Detection of smooth muscle α-actin (α-SMA) protein in human cells was
performed with the use of an immunoperoxidase technique and the ABCVectastain Elite kit (Vector Laboratories, Inc., Burlingame, CA, USA) according
to the supplier's directions with some modifications. Primary human skin
fibroblasts were seeded and grown onto poly-L-lysine-coated glass slides,
washedwith PBS, and then fixedwith freshly prepared 3% paraformaldehyde for
10 min. Cells were permeabilized with 0.25% Triton X-100 (Sigma Chemical
Co., St. Louis, MO, USA) in PBS for 10 min and washed with PBS again. After
blocking of the endogenous peroxidase activity with 1.5% hydrogen peroxide in
methanol for 30min, the slides were heated for antigen retrieval in a water-bath at
95 °C in citrate buffer, allowed to cool down, and then incubated with 1% normal
horse serum in PBS for 30 min. Mouse anti-α-SMA antibody at a dilution of
1:400 was incubated overnight at 4 °C, followed by biotinylated horse anti-
mouse and the avidin–biotin–peroxidase complex. Washes were performed 3
times with PBS after each incubation step. Peroxidase activity was developed by
a solution of 3–3′ diaminobenzidine tetrahydrochloride (DAB) (Vel, Leuven,
Belgium) dissolved in PBS and 0.03%H2O2. The DAB solution was filtered and
applied to the sections for 3 min. Finally, Carazzi's hematoxylin was used to
counterstain the slides that were then dehydrated and mounted. Experiments in
which the first antibody was omitted in the assay were used as controls.
Photomicrographs of the slides were taken with a Zeiss microscope.
2.6. Real-time reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNAwas extracted using the RNeasy mini kit (Qiagen, Inc., Valencia,
CA), according to the manufacturer's protocol. For cDNA synthesis, 0.5 to 2 μg
of total RNA were reverse transcribed in a 20-μL reaction mixture containing
0.2 μg of random hexamers (AmershamBiosciences, Little Chalfont, UK), 2mM
of each deoxynucleotide triphosphate (dNTP) (Eurogentec, Seraing, Belgium),
1×first-strand buffer (50 mM Tris/HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2)
(Invitrogen), 10mMdithiothreitol (Invitrogen), and 100 units of SuperScript™ II
RNase H reverse transcriptase (Invitrogen). The RT reaction was performed at
42 °C for 50 min before a 15-min inactivation step at 70 °C. Reactions not
containing the reverse transcriptase were used as controls. Quantitative real-time
PCR was performed using the ABI Prism 7300 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer's
instructions. PCRwas performed using the TaqMan®PCRUniversalMasterMix
(Applied Biosystems). The sequences of the primers and probes for the human
HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and
α-SMA genes were designed using the Primer Express software (Applied
Biosystems)[31]. Taqman® primers and probes for the human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), β-actin, 18S RNA, cyclophilin A, 5′-TG-
3′-interacting factor (TGIF, also termed TGF-ß-interacting factor), 5′-TG-3′-
interacting factor 2 (TGIF2), and Sma andMad-related protein 7 (SMAD7) genes
were purchased from Applied Biosystems. All sets of primers and probes were
selected to work under similar cycling conditions. cDNA samples (100 ng each)
were mixed with 100 nM of each primer and TaqMan® Universal PCR Master
Mix containing 1×PCR buffer, 5.5 mM MgCl2, 0.8 mM dNTPs mix, 100 nM
probe and 1 unit of AmpliTaq Gold® thermostable DNA polymerase (Applied
Biosystems) in a total volume of 25 μL. Taqman® real-time PCR was performed
for each target cDNA and transcript expression levels were normalized to those of
GAPDH, 18S RNA, or cyclophilin A. All samples were run as triplicates.
Acquired data were analyzed using the Sequence Detector software (Applied
Biosystems).
2.7. Lactate dehydrogenase (LDH) release assay
In order to assess any potential cytotoxicity associated with TSA treatment or
siRNA transfection of the cells, LDH activity in culture supernatants (triplicate
per each condition) was determined using the fluorescent-base CytoTox-One
homogenous membrane integrity assay (Promega Corp., Madison, WI, USA),
according to the manufacturer's instructions.
2.8. Statistical analysis
Expression ratios were associated with their standard errors. An asympto-
tically Normal test was used to test for differences in expression ratios between
two different experimental conditions. Unless otherwise specified, expression
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cells. Differences were considered significant when pb0.05.
3. Results
3.1. Trichostatin A, a global class I and class II HDAC
inhibitor, prevents TGFβ1-mediated MF differentiation
To first examine the potential implication of HDACs in the
process of TGFβ1-induced fibroblast-to-myofibroblast differ-
entiation, human skin fibroblasts were exposed to TGFβ1 and/or
trichostatin A (TSA) for 24 and 48 h. Morphological changes
were then assessed and relative amounts of α-SMA transcript
and protein levels were evaluated by real time Taqman® RT-
PCR and Western blot/immunocytochemistry, respectively. As
shown in Fig. 1A, TGFß1 treatment resulted expectedly in a
markedly increased production of α-SMA by fibroblasts, as
determined by Western blot analysis. In contrast, TSA down-
regulated the abundance of α-SMA in cells either exposed to
TGFβ1 or not, and completely suppressed the TGFβ1-inducedFig. 1. Trichostatin A (TSA), a global class I and class II HDAC inhibitor, prevents
human primary fibroblasts with TGFβ1 (2.5 ng/mL), TSA (500 nM) or their respect
protein was assessed using immunoblot (A), immunocytochemistry (B) and real tim
repeated at least twice and consistent results were observed. Statistically significant re
TSA-untreated conditions, either in absence or in presence of TGFβ1, are indicatedoverexpression of this cytoskeletal protein. The efficiency of
HDAC inhibition by TSAwas verified by analyzing the amount
of acetylated α-tubulin, which was clearly augmented in the
TSA-treated cells, in agreement with previous studies [28,32].
TGFβ1 not only can trigger the expression of α-SMA, one of
the major markers of MF differentiation, but also can induce
morphological changes that are intermediate between those
featured by fibroblasts and smooth muscle cells. With the use of
immunocytochemistry to detect α-SMA in fibroblasts treated
with or without TGFβ1 for 48 h, we observed that themajority of
the TGFß1-treated cells expressed α-SMA that exhibited a
cytoplasmic cable-like distribution and displayed typical MF
morphology with cellular hypertrophy (Fig. 1B). In contrast,
only a very small proportion of the fibroblasts not exposed to
exogenous TGFβ1 exhibited such MF features. Importantly,
TSA treatment fully prevented the induction of TGFβ1-
mediated MF changes and reverted the small MF-like sub-
population present in the TGFβ1-non-treated condition to a
fibroblastic phenotype. None of the TSA-treated fibroblasts
displayed evident α-SMA expression. We thus concluded thatTGFβ1-mediated myofibroblastic differentiation. After 24 or 48 h treatment of
ive vehicle (PBS and DMSO), the relative abundance of α-SMA transcript and
e RT-PCR (C), as described in Materials and methods. Each experiment was
ductions in relative α-SMA transcript levels (pb0.05) between TSA-treated and
as an asterisk.
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prevent TGFβ1-mediated MF differentiation of human skin
fibroblasts in vitro, as assessed morphologically as well as
biochemically by analyzing cellular α-SMA abundance.
Since HDACs play a key role in the regulation of gene
transcription by modifying core histone acetylation levels, we
next asked whether TSA was able to influence α-SMA mRNA
steady-state abundance in fibroblasts treated with or without
TGFβ1. As shown in Fig. 1C, while TGF-β1 treatment induced
a±3–4 fold increase in α-SMA mRNA steady-state levels
(normalized to GAPDH mRNA levels), TSA treatment resulted
in decreased levels of the transcript at both 24 and 48 h time
points (2 fold decrease after 48 h of treatment; pb0.05). TGFβ1-
mediated increase in α-SMA mRNA levels was significantly
impaired when the cells were concomitantly exposed to TSA
(pb0.05). Similar results were obtained when other reference
genes, including cyclophilin A, β-actin, and 18S RNA, were
used for normalizing α-SMA transcripts levels in the RT-PCR
experiments (data not shown). Therefore, global inhibition of
class I and class II HDAC activities was shown to repress α-
SMA expression possibly at the transcriptional level. This
repressive activity exerted by TSA was dose-dependent (Fig.
2A) and was not due to a cytotoxic effect. Indeed, whenFig. 2. TSA represses α-SMA transcript expression by human primary fibroblasts in
fibroblasts were treated with TGFβ1 (2.5 ng/mL) and/or TSA at various concentrati
TGFß1 (2.5 ng/mL) and DMSO (condition C1) or with TGFβ1 (2.5 ng/mL) and TSA
with TGFβ1 (2.5 ng/mL) and DMSO (no TSA). (A) The relative abundance of α-SMA
RT-PCR, as described in Materials and methods. (B) Lactate dehydrogenase (LD
membrane integrity assay to evaluate potential cytotoxicity associated with TSA trea
were observed. Data were expressed as means±standard deviation. Statistically signi
TSA-treated and TSA-untreated conditions, either in absence or in presence of TGFfibroblasts were relieved from TSA after 48 h of treatment,
TGFß1 was still able to induce α-SMA transcript expression
(Fig. 2A). Furthermore, TSA treatment did not significantly
increase lactate dehydrogenase (LDH) activity levels in culture
supernatants (Fig. 2B).
3.2. Influence of specific HDAC silencing on TGFβ1-mediated
β-SMA induction
We next sought to determine which HDAC(s) might be
involved in the process of TGFβ1-mediated MF differentiation.
To this end, fibroblasts were transfected with siRNAs directed
against most class I and class II HDACs (HDAC1 through
HDAC8) for 16 h and then treated with TGFβ1 for 48 h. The
capacity of each siRNA to silence its target HDAC was checked
by real time RT-PCR analysis. Each siRNA transfection was
found to reduce by at least 70% the amount of the
corresponding HDAC mRNA, with the exception of HDAC8
(Fig. 3A). In addition, TGFβ1 treatment of the cells did not
substantially affect the mRNA level of all the HDACs tested
(less than 20% variation; data not shown).
Fold inductions of α-SMA transcript expression by TGFβ1
(±3–4 fold) were similar in fibroblasts transfected withouta dose-dependent manner without triggering cellular toxicity. Human primary
ons (0, 50, 200, and 500 nM) for 48 h. Fibroblasts were also treated either with
(500 nM) (condition C2) for 48 h, and then further for 48 h in both conditions
transcripts was assessed in the different experimental conditions using real time
H) activity in culture supernatants was determined using a fluorescent-based
tment of the cells. Each experiment was performed twice and consistent results
ficant differences in α-SMA transcript levels and in LDH activity levels between
β1, are indicated as an asterisk (pb0.05).
Fig. 3. Screening of the influence of specific HDAC silencing on TGFβ1-mediated myofibroblastic differentiation. Primary human fibroblasts were transfected with
siRNAs directed against each of the 8 first members of the HDAC family (HDAC1 through HDAC8) and then treated with or without TGFβ1 (2.5 ng/mL in PBS) for
48 h. Mock transfections with transfection reagent alone served as negative control. Controls also included three different RNA duplexes: a scrambled version of
HDAC4 siRNA (scHDAC4 siRNA), a siRNA directed against GL3 luciferase (GL3 Luc), and Eurogentec (EGT) negative control siRNA. The relative transcript levels
of each HDAC (A) as well as those of α-SMA (B) (normalized to GAPDH transcript levels) were assessed by real time RT-PCR, as described in Materials and
methods. Each experiment was repeated at least twice and consistent results were observed. Data were expressed as mean ratios±standard deviation. Statistically
significant differences in relative α-SMA transcript levels between control cells (mock-, EGT siRNA-, GL3 Luc siRNA-, and scHDAC4 siRNA-transfected cells) and
cells transfected with each specific HDAC siRNA are indicated as an asterisk (pb0.05).
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HDAC1, HDAC3, HDAC5 or with various control siRNAs
(EGT negative control siRNA, GL3 luciferase siRNA, or a
scrambled HDAC4 siRNA) (pN0.05). A weaker TGFβ1-
mediated α-SMA induction (±2 fold) was observed in
HDAC6- and HDAC8-silenced cells (pb0.05) while a stronger
α-SMA transcript induction (±6–7 fold) was found in HDAC2-
and HDAC7-silenced, TGFβ1-treated fibroblasts (pb0.05)
(Fig. 3B). Among the HDACs investigated, it appeared that
HDAC4 silencing most efficiently abrogated TGFβ1-induced
α-SMA overexpression. Thus, while global inhibition of class I
and class II HDACs by TSA lead to a complete prevention of
TGFβ1-mediated α-SMA induction, the specific silencing of a
number of these HDACs yielded various effects on α-SMA
abundance (stronger, weaker, or similar induction). Since
HDAC4 silencing resulted in the most profound blocking ofα-SMA induction – similar to that obtained when fibroblasts
were treated with TSA – we further attempted to characterize
the impact of HDAC4 in TGFβ1-mediated MF differentiation.
3.3. HDAC4 is necessary for TGFβ1-mediated MF
differentiation
We first evaluated the toxicity of HDAC4 RNA interference
using 3 different siRNAs directed against human HDAC4
mRNA. Measurements of LDH activity levels in culture
supernatants following transfection of the cells with these
siRNAs showed no cytotoxic effect of the siRNAs as compared
with mock-, scrambled HDAC4 siRNA, and EGT negative
control siRNA transfections (data not shown). In addition, no
induction of 2′, 5′-oligoadenylate synthase-1 (OAS-1) transcript
expression was observed following siRNA transfections (data
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not trigger any interferon response by the transfected cells.
Among the 3 HDAC4 siRNAs tested, HDAC4 siRNA#2 and
HDAC4 siRNA#3 most efficiently down-regulated HDAC4
transcripts in fibroblasts while the silencing effect of HDAC4
siRNA#1 was more modest (pb0.05) (Fig. 4A). As shown in
Fig. 4B, TGFβ1-mediated α-SMA transcript induction was
prevented in fibroblasts transfected with the most efficient
HDAC4 siRNAs (#2 and #3) (pb0.05) while it was only
modestly repressed in fibroblasts transfected with the less
efficient HDAC4 siRNA#1 (pb0.05). In addition, HDAC4
silencing did not significantly decrease the transcript levels of
HDAC1 through HDAC8 (Fig. 5A) (pN0.05). Similar results
were observed when 2 reference genes, GADPH and β-actin,
were used for normalizing α-SMA transcripts levels in the RT-
PCR experiments (data not shown).
At the protein level, immunoblot analysis showed that
silencing of HDAC4 using HDAC4 siRNAs #2 and #3
prevented the induction of α-SMA expression mediated by
TGFβ1 (Fig. 5B). This repressive effect was weaker in HDAC4
siRNA#1-transfected cells. Immunocytodetection of α-SMAFig. 4. HDAC4 is necessary for TGFβ1-mediated myofibroblastic differentia-
tion. Primary human fibroblasts were transfected with 3 different siRNAs
directed against HDAC4 and then treated with or without TGFβ1 (2.5 ng/mL in
PBS) for 48 h. Mock transfections with transfection reagent alone and
transfections with Eurogentec negative control siRNA served as negative
controls. The relative levels of HDAC4 (A) and α-SMA (B) transcripts
(normalized to GAPDH transcript levels) were assessed by real time RT-PCR, as
described in Materials and methods. Each experiment was repeated at least twice
and consistent results were observed. Statistically significant reductions in
relative HDAC4 and α-SMA transcript levels between mock-transfected cells
and cells transfected with each of the other siRNAs, either in absence or in
presence of TGFβ1, are indicated as an asterisk (pb0.05).confirmed the immunoblot data and further showed that HDAC4
silencing using HDAC 4 siRNAs #2 and #3 fully prevented the
induction of MF morphologic changes mediated by TGFβ1
(Fig. 6). Therefore, these results indicated that HDAC4 is
required for efficient TGFβ1-mediated MF differentiation.
3.4. HDAC4 silencing induces the expression of TGIF and
TGIF2, two endogenous inhibitors of the TGFβ1 signaling
pathway
Since histone deacetylases are usually associated with
repression of gene expression, we next sought to investigate
whether HDAC4 silencing would result in the induction of
known endogenous inhibitors of the TGFβ pathway, including
Smad7 [33–37], 5′-TG-3′-interacting factor (TGIF), and 5′-TG-
3′-interacting factor 2 (TGIF2). As shown in Fig. 7, TGFβ1
slightly upregulated the transcripts of these inhibitors. No
significant increase in Smad7 mRNA levels was observed in
HDAC4-silenced TGFβ1-treated fibroblasts (pN0.05). In con-
trast, HDAC4 silencing in fibroblasts resulted in increased levels
of TGIF and TGIF2 transcripts, whether cells were exposed to
TGFβ1 or not (pb0.05).
4. Discussion
With the exception of a subset of myofibroblasts residing in
specific normal human tissues [31], most myofibroblasts are
thought to arise locally from resident fibroblasts as a con-
sequence of tissue injury and acquire some of the contractile
proteins normally expressed by smooth muscle cells such as α-
SMA. These hypertrophic stromal cells typically contain
numerous smooth muscle actin stress fibers that contribute to
the generation of isometric mechanical force required for wound
contraction and closure [13,38]. Chronic myofibroblast activa-
tion has been associated with a number of pathological
conditions associated with tissue remodeling, including hyper-
trophic scarring, interstitial fibrosis, and stromal response to
certain neoplasias. TGFβ1 is commonly considered as a master
molecule for the general MF activation program. Other
cytokines and growth factors, such as platelet-derived growth
factor and tumor necrosis factor-α, do also bear profibrotic
activity, but do not induce α-SMA in fibroblasts [3].
In this study, we have shown that inhibition of class I and
class II HDAC activities by TSA abrogates TGFβ1-mediated de
novo α-SMA transcript and protein expression and morpholo-
gical changes characteristic of MF differentiation in human skin
fibroblasts. These findings are consistent with those of a
previous study by Rombouts et al., who have reported that
TSA suppresses the inductive effect of TGFβ1 on α-SMA
mRNA abundance in rat skin fibroblasts [24]. TSA treatment has
also been shown to interfere with other biological processes
mediated by TGFß1, such as the epithelial-to-mesenchymal
transition of human renal proximal tubular epithelial cells [39]
and the repression of the interferon α-induced MHC II
transactivator (CIITA) gene in mouse microglial cells[40].
Thus, the results of our current study not only suggest that global
HDAC inhibition may be a useful approach to prevent TGFß1-
Fig. 5. (A) HDAC4 silencing does not significantly modify the transcript levels of HDAC1 through HDAC8 in primary human fibroblasts. Primary human fibroblasts
were transfected with a siRNA directed against HDAC4 (HDAC4 siRNA#2). Mock transfections with transfection reagent alone and transfections with Eurogentec
negative control siRNA served as negative controls. The relative transcript levels of HDAC1 through HDAC8 (normalized to GAPDH transcript levels) were assessed
by real time RT-PCR, as described in Materials and methods. Data were expressed as mean ratios±standard deviation. Statistically significant reductions in relative
HDAC transcript levels between cells transfected with HDAC4#2 siRNA and both mock- and EGT siRNA-transfected cells are indicated as an asterisk (pb0.05). (B)
TGFβ1 fails to induce α-SMA protein expression in the absence of HDAC4 in primary human fibroblasts. Primary human fibroblasts were transfected with 3 different
siRNAs directed against HDAC4 and then treated with or without TGFß1 (2.5 ng/mL in PBS) for 48 h. Mock transfections with transfection reagent alone and
transfections with Eurogentec (EGT) negative control siRNA served as negative controls. The relative levels of α-SMA, HDAC4, α-tubulin, and β-actin were assessed
by immunoblot, as described in Materials and methods. Lanes marked by an ⁎ (α-SMA and α-tubulin) were loaded with total protein extracts from primary human
smooth muscle cells. Lanes marked by a # (HDAC4 and β-actin) were loaded with total protein extracts from Saos2 cells transfected with a flag-tagged human HDAC4
expression vector. Experiments were repeated at least twice and consistent results were observed.
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evidence indicating that TGFß1mediates its biological functions
at least in part by epigenetic mechanisms of gene regulation
involving histone deacetylase activities.
The negative impact of TSA on TGFβ1-mediated MF
differentiation obviously represents the net effect of the
cumulative inhibitory activity of the drug on all sensitive
HDACs present within the fibroblasts. In order to investigate the
involvement of individual HDACs in this process, we have
evaluated the impact of specific HDAC gene silencing by RNA
interference on α-SMA gene expression by fibroblasts treated
with TGFβ1. Silencing of each of the eight first members of the
histone deacetylase family resulted in diverse effects on α-SMA
transcript abundance. On one hand, forced downregulation of
HDAC4, HDAC6, and HDAC8 repressed TGFβ1-mediated α-
SMA transcript levels; the most profound repression was
observed with HDAC4 silencing, which resulted in an almost
complete failure of TGFβ1-treated fibroblasts to overexpress α-
SMA transcript and protein. Thus, at least 3 different HDACs
may operate to drive or promote TGFβ1-mediated myofibro-blastic differentiation. On the other hand, while knockdown of
HDAC1, HDAC3, and HDAC5 had no effect on α-SMA
transcript expression, silencing of HDAC2 and HDAC7
substantially potentiated the induction of α-SMA transcript in
response to TGFβ1 exposure. The differential effects of each
specific HDAC silencing on α-SMA expression are not
unexpected and are in keeping with the results of previous
reports on TGFß1-responsive genes. Indeed, prior studies have
shown opposed effects of different HDAC inhibitors on the
expression of one single gene (e.g. TSA/sodium butyrate versus
valproic acid on Timp-1 expression [41]) as well as divergent
impacts of one single HDAC inhibitor on the expression of
different genes (e.g. TSA on type I collagen versus PAI-1 [26]).
Sirtuins have not been considered in this study. However, these
class III HDAC's may also prove in the future to be involved in
theMF differentiation program. Indeed, it has been very recently
shown that SIRT1, through its capacity to promote the
deacetylation of Smad7 (and subsequently its ubiquitin/protea-
some-mediated degradation), attenuates TGFβ1-induced apop-
tosis of murine mesangial cells [20].
Fig. 6. HDAC4 silencing prevents TGFβ1-mediated induction of myofibro-
blastic morphologic changes in primary human fibroblasts. Primary human
fibroblasts were transfected with 3 different siRNAs directed against HDAC4
and then treated with TGFβ1 or vehicle (PBS). Mock transfections with
transfection reagent alone and transfections with Eurogentec (EGT) negative
control siRNA served as negative controls. Expression of α-SMAwas assessed
by immunocytostaining, as described in Materials and methods. Experiments
were repeated at least twice and consistent results were observed.
Fig. 7. HDAC4 silencing induces the expression of TGIF and TGIF2, two
endogenous inhibitors of the TGFβ1 signaling pathway, in primary human
fibroblasts. Primary human fibroblasts were transfected with a siRNA directed
against HDAC4 (HDAC4 siRNA#2), with transfection reagent alone, with
Eurogentec negative control siRNA, or with a scrambled HDAC4 siRNA
(scHDAC4#2 siRNA), and then treated with TGFβ1 or vehicle (PBS). The
relative levels of Smad7, TGIF, and TGIF2 transcripts were assessed by real time
RT-PCR analysis, as described inMaterials and methods. Data were expressed as
mean ratios±standard deviation. Statistically significant increases in relative
Smad7, TGIF, and TGIF2 transcript levels between cells transfected with
HDAC4#2 siRNA and mock-, scrambled HDAC4#2 siRNA, and EGT siRNA-
transfected cells are indicated as an asterisk (pb0.05). Experiments were
repeated at least twice and consistent results were observed.
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TGFß1-mediated MF transdifferentiation, as assessed phenoty-
pically. Remarkably, under our experimental conditions,
HDAC4 silencing was almost as efficient as TSA to prevent
the induction of α-SMA gene expression by TGFβ1. In fact, it
may not be intriguing that HDAC4 is necessary for MF
differentiation. This HDAC indeed represents a major con-
tributor to several other differentiation programs, including
those related to osteoblasts [42], chondrocytes [43], and muscle
cells [44–48]. Whether common pathways are affected during
these differentiation processes remains to be elucidated.
Since HDAC activities are generally associated with tran-
scriptional repression and the stimulation of α-SMA expressionby TGFβ1 is repressed by HDAC4 silencing, we have reasoned
that HDAC4 silencing may exert its negative regulation on
α-SMA expression by inducing endogenous repressing activ-
ities of the TGFß pathway. In other words, HDAC4 may be
necessary to silence the expression of TGFβ pathway repressors
to enable α-SMA expression. In addition, it has been previously
observed that the inhibitory effect of TSA on TGFβ1-mediated
α-SMA transcription is cycloheximide-sensitive, i.e. requiring
de novo protein synthesis of a putative TGFβ pathway repressor
[24]. Other potential mechanisms by which HDAC4 silencing
may negatively affect the expression of α-SMA encompass
1581W. Glenisson et al. / Biochimica et Biophysica Acta 1773 (2007) 1572–1582direct hyperacetylation – and subsequent stabilization and/or
increased activity – of transcriptional corepressors of theα-SMA
gene and HDAC4 deacetylase activity-independent effects. A
number of TGFß pathway repressors have been characterized and
include the well known inhibitory Smad7 protein [33,37] as well
as TGIF and TGIF2. The latter are DNA-binding homeoproteins,
which share two major blocks of similarity encompassing the
homeodomain and a conserved carboxyl terminal repression
domain and act as TGFβ specific Smad transcriptional
corepressors through direct interactions with Smad2, Smad3,
the Sin3 corepressor complex and HDAC1 [49–51]. TGIF may
also be a component of a ubiquitin ligase complex that mediates
the degradation of Smad2 in response to TGFß signaling [52].
Previous studies have shown that (i) Smad7 inhibits α-SMA
expression in different cell types [53,54], (ii) ectopic expression
of TGIF markedly suppresses Smad-mediated activation of
TGFß1-responsive promoter activity and completely blocks
TGFß1-inducedα-SMA expression in cultured rat andmesangial
cells [55] and (iii) TSA upregulates the expression of both TGIF
and Smad7 transcripts in TGFß1-treated rat fibroblasts [24].
Therefore, we have been interested to find out whether HDAC4
silencing would result in an upregulation of these TGFβ pathway
repressor molecules. We have found that Smad7, TGIF, and
TGIF2 transcript abundance was increased in response to TGFß1
treatment, which is in agreement with previous studies suggest-
ing that these proteins may act as negative feedback effectors to
desensitize TGFβ1 action [24,56,57]. However, when fibroblasts
were transfectedwith HDAC4 siRNAs, TGIF andTGIF2, but not
Smad7 transcript levels were significantly upregulated, suggest-
ing that (i) HDAC4 is involved in the regulation of the two
homeodomain proteins and (ii) HDAC4 silencing mediates its
inhibitory effects on TGFß1-mediated phenotypic changes
through TGIF and TGIF2 induction. In addition, to our know-
ledge, these are the first data to indicate that TGIF and TGIF2
expression may be regulated by a HDAC. It will take another
study to dissect the precise mechanisms whereby HDAC4
regulates TGIF and TGIF2 expression.
Overall, the data presented in the current study point at a
necessary role for HDAC4 in the phenotypic transition of fibro-
blasts to myofibroblasts mediated by TGFß1, thereby unveiling
HDAC4 as a potential target for treating MF differentiation-
related pathological conditions.
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